Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma.

@article{Kuzel1996PhaseIT,
  title={Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma.},
  author={Timothy Michael Kuzel and Anju Hurria and Ellen Samuelson and Martin S. Tallman and Henry H Roenigk and Alfred W. Rademaker and Steven T. Rosen},
  journal={Blood},
  year={1996},
  volume={87 3},
  pages={906-11}
}
We investigated the efficacy of 2-chlorodeoxyadenosine (2-CdA) therapy in patients with mycosis fungoides (MF) and the Sezary syndrome (SS). Between February 1991 and November 1993, 21 patients with relapsed or refractory MF/SS were treated with 2-CdA. 2-CdA was administered by continuous intravenous infusion at a dose of 0.1 mg/kg/d for 7 days initially (13 patients), but was subsequently reduced to 5 days (nine patients) due to hematologic toxicity. All patients had failed to respond to at… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

Similar Papers

Loading similar papers…